Revolutionizing Cardiac Care: inHEART Secures $11M in Funding
May 10, 2024, 9:36 pm
inHEART, a medical device company, has secured $11 million in funding to propel the development and deployment of innovative cardiac solutions. The funding, led by Vesalius Biocapital IV and co-led by Elaia Partners, will support the expansion of inHEART's digital twin of the heart and the creation of new software solutions across the cardiac care continuum.
The digital twin of the heart, powered by AI technology, aims to revolutionize patient care by providing personalized therapy and predictive screening for cardiac diseases. CEO Todor Jeliaskov expressed excitement about the potential impact of this funding, stating that it will enable inHEART to address the needs of cardiac patients from early detection to advanced therapeutic support.
The funding will also drive the development of AI-driven predictive models for conditions like heart failure and sudden cardiac death, as well as a new therapeutic software solution to aid physicians in treating heart failure patients. Currently available in the US and EU, inHEART plans to establish a global distribution network to further accelerate its growth and impact in the healthcare industry.
Key stakeholders, including investors and board members, have expressed enthusiasm for inHEART's innovative approach to cardiac care. Samantha Jérusalmy, a board member at inHEART, highlighted the precision and effectiveness of inHEART's AI-driven 3D cardiac mapping in treating heart conditions. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV, emphasized the importance of supporting advancements in medical technology that improve patient care.
In conclusion, inHEART's recent funding round marks a significant milestone in the company's mission to transform cardiac care through cutting-edge technology and innovation. With a focus on personalized therapy, predictive screening, and advanced therapeutic solutions, inHEART is poised to make a lasting impact on the healthcare industry and the lives of cardiac patients worldwide.
The digital twin of the heart, powered by AI technology, aims to revolutionize patient care by providing personalized therapy and predictive screening for cardiac diseases. CEO Todor Jeliaskov expressed excitement about the potential impact of this funding, stating that it will enable inHEART to address the needs of cardiac patients from early detection to advanced therapeutic support.
The funding will also drive the development of AI-driven predictive models for conditions like heart failure and sudden cardiac death, as well as a new therapeutic software solution to aid physicians in treating heart failure patients. Currently available in the US and EU, inHEART plans to establish a global distribution network to further accelerate its growth and impact in the healthcare industry.
Key stakeholders, including investors and board members, have expressed enthusiasm for inHEART's innovative approach to cardiac care. Samantha Jérusalmy, a board member at inHEART, highlighted the precision and effectiveness of inHEART's AI-driven 3D cardiac mapping in treating heart conditions. Jean-Christophe Renondin, Managing Partner at Vesalius Biocapital IV, emphasized the importance of supporting advancements in medical technology that improve patient care.
In conclusion, inHEART's recent funding round marks a significant milestone in the company's mission to transform cardiac care through cutting-edge technology and innovation. With a focus on personalized therapy, predictive screening, and advanced therapeutic solutions, inHEART is poised to make a lasting impact on the healthcare industry and the lives of cardiac patients worldwide.